Optimized subunit vaccine protects against experimental leishmaniasis

被引：80
作者：
Bertholet, Sylvie [1 ]
Goto, Yasuyuki [1 ]
Carter, Lauren [1 ]
Bhatia, Ajay [1 ]
Howard, Randall F. [1 ]
Carter, Darrick [1 ]
Coler, Rhea N. [1 ]
Vedvick, Thomas S. [1 ]
Reed, Steven G. [1 ]
机构：
[1] Infect Dis Res Inst, Seattle, WA 98104 USA
来源：
VACCINE | 2009年 / 27卷 / 50期
基金：
美国国家卫生研究院; 比尔及梅琳达.盖茨基金会;
关键词：
Leishmania; vaccination; MPL; MONOPHOSPHORYL-LIPID-A; HEPATITIS-B-VACCINE; CD8(+) T-CELLS; RECOMBINANT POLYPROTEIN VACCINE; CANINE VISCERAL LEISHMANIASIS; IMMUNE-RESPONSE; CUTANEOUS LEISHMANIASIS; INFANTUM INFECTION; CANCER-PATIENTS; ADJUVANT;
D O I：
10.1016/j.vaccine.2009.09.066
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Development of a protective subunit vaccine against Leishmania spp. depends on antigens and adjuvants that induce appropriate immune responses. We evaluated a second generation polyprotein antigen (Leish-110f) in different adjuvant formulations for immunogenicity and protective efficacy against Leishmania spp. challenges. Vaccine-induced protection was associated with antibody and T cell responses to Leish-110f. CD4 T cells were the source of IFN-gamma, TNF, and IL-2 double- and triple-positive populations. This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：7036 / 7045
页数：10
相关论文
共 58 条
[1]   Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose [J].
Aagaard, Claus ;
Hoang, Truc Thi Kim Thanh ;
Izzo, Angelo ;
Billeskov, Rolf ;
Troudt, JoLynn ;
Arnett, Kim ;
Keyser, Andrew ;
Elvang, Tara ;
Andersen, Peter ;
Dietrich, Jes .
PLOS ONE, 2009, 4 (06)
[2]   Design and selection of vaccine adjuvants: animal models and human trials [J].
Alving, CR .
VACCINE, 2002, 20 :S56-S64
[3]  
ANDERSON RC, 2009, COLLOIDS SURF B 0820
[4]   Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents [J].
Baldridge, JR ;
McGowan, P ;
Evans, JT ;
Cluff, C ;
Mossman, S ;
Johnson, D ;
Persing, D .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) :1129-1138
[5]   Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion [J].
Baldwin, Susan L. ;
Shaverdian, Narek ;
Goto, Yasuyuki ;
Duthie, Malcolm S. ;
Raman, Vanitha S. ;
Evers, Tara ;
Mompoint, Farah ;
Vedvick, Thomas S. ;
Bertholet, Sylvie ;
Coler, Rhea N. ;
Reed, Steven G. .
VACCINE, 2009, 27 (43) :5956-5963
[6]   Intradermal immunization improves protective efficacy of a novel TB vaccine candidate [J].
Baldwin, Susan L. ;
Bertholet, Sylvie ;
Kahn, Maria ;
Zharkikh, Irina ;
Ireton, Gregory C. ;
Vedvick, Thomas S. ;
Reed, Steven G. ;
Coler, Rhea N. .
VACCINE, 2009, 27 (23) :3063-3071
[7]   Inflammasomes in inflammatory disorders: The role of TLRs and their interactions with NLRs [J].
Becker, Christine E. ;
O'Neill, Luke A. J. .
SEMINARS IN IMMUNOPATHOLOGY, 2007, 29 (03) :239-248
[8]   Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate [J].
Becker, R ;
Eichler, MK ;
Jennemann, R ;
Bertalanffy, H .
BRITISH JOURNAL OF NEUROSURGERY, 2002, 16 (03) :269-275
[9]   CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major [J].
Belkaid, Y ;
Von Stebut, E ;
Mendez, S ;
Lira, R ;
Caler, E ;
Bertholet, S ;
Udey, MC ;
Sacks, D .
JOURNAL OF IMMUNOLOGY, 2002, 168 (08) :3992-4000
[10]   Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells [J].
Bertholet, S ;
Debrabant, A ;
Afrin, F ;
Caler, E ;
Mendez, S ;
Tabbara, KS ;
Belkaid, Y ;
Sacks, DL .
INFECTION AND IMMUNITY, 2005, 73 (10) :6620-6628
123456